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Abstract
The papain family of cysteine cathepsins are actively involved in multiple stages of tumorigenesis. Because elevated
cathepsin activity can be found in many types of human cancers, they are promising biomarkers that can be used to target
radiological contrast agents for tumor detection. However, currently there are no radiological imaging agents available for
these important molecular targets. We report here the development of positron emission tomography (PET) radionuclide-
labeled probes that target the cysteine cathepsins by formation of an enzyme activity-dependent bond with the active site
cysteine. These probes contain an acyloxymethyl ketone (AOMK) functional group that irreversibly labels the active site
cysteine of papain family proteases attached to a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) tag for
labeling with
64Cu for PET imaging studies. We performed biodistribution and microPET imaging studies in nude mice
bearing subcutaneous tumors expressing various levels of cysteine cathepsin activity and found that the extent of probe
uptake by tumors correlated with overall protease activity as measured by biochemical methods. Furthermore, probe
signals could be reduced by pre-treatment with a general cathepsin inhibitor. We also found that inclusion of a Cy5 tag on
the probe increased tumor uptake relative to probes lacking this fluorogenic dye. Overall, these results demonstrate that
small molecule activity-based probes carrying radio-tracers can be used to image protease activity in living subjects.
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Introduction
Proteases play important roles in the regulation of both normal
and disease processes. In particular, the papain family cysteine
cathepsins are frequently over-expressed in a number of human
cancers [1-7]. In addition, expression of a number of cysteine
cathepsin including cathepsins B and L is increased in pre-
neoplastic lesions and changes in both localization and sub-cellular
distribution of these proteases are often observed in tumors [1,3,7].
This combination makes them potentially valuable cancer
biomarkers [1–5,8,9]. Novel imaging methods and molecularly
targeted tracers can now be used not only to locate a tumor, but
also to visualize the expression and activity of specific molecular
targets and biological processes in a tumor [10,11]. These imaging
methods have the potential to facilitate both early disease
detection and to aid in the process of drug development by
allowing non-invasive monitoring of target inhibition. Directed
targeting of enzymatic proteins such as proteases using imaging
agents also has the potential to provide greater detail about the
basic biological framework of a tumor and provide better
resolution of the disease phenotype [10,12–16].
Since most proteases are initially synthesized as inactive
zymogens that are activated by a complex set of post-translational
mechanisms, tools that report on enzyme activity rather than
protein abundance will be required to fully understand their
function in complex biological processes. For this reason, a
number of recent studies have focused on the development of
imaging agents that act as substrates for a target protease
[10,13,15,16]. In addition, fluorescent molecules that only
penetrate a cellular membrane when processed by a target
protease have been developed [17–19]. While all of these methods
have provided valuable new tools, none of these methods have
been translated for use in radiological imaging.
We report here the development and application of radio-
labeled small molecule activity-based probes (ABPs) that can be
used for positron emission tomography (PET) imaging of cysteine
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e28029cathepsin activity. These probes are based on the peptide
acyloxymethyl ketones (AOMKs) that have been reported to be
highly selective labels of a number of classes of cysteine cathepsins
[20]. This class of reagents has also recently been used for optical
imaging of cysteine cathepsin activity in live cells [8] and in near-
infrared fluorescent (NIRF) labeled form for non-invasive optical
imaging of cysteine cathepsin activity in living subjects [21,22].
The probes presented here couple the intrinsic advantages of
nuclear imaging, including high sensitivity, capability of quanti-
fication, and clinical translation, with the specific, covalent nature
of these imaging agents. In addition, their relatively small size
compared to substrate based probes provides favorable in vivo
pharmacodynamic properties and cellular uptake. Thus, probes
presented here represent potentially valuable new imaging tools
for application to a number of clinically relevant diseases that
involve increased cysteine cathepsin activity.
Results
Generation of a PET Probe Based On the GB123 Structure
ABPs provide an indirect readout of protease activity in
complex proteomes. A number of ABPs targeting various cysteine
cathepsins have recently been reported [20,21,23,24]. In partic-
ular, the peptide acyloxymethyl ketones have been validated in
optical imaging applications [8,21,22,25]. The covalent modifica-
tion of a cysteine protease by an AOMK results in alkylation of the
active site thiol and loss of acyloxy group (Figure 1A). One of the
initially reported AOMK derivatives, Z-FR-AOMK, exhibited
high potency and specificity for cathepsin B and L [20]. Moreover,
conversion of Z-FR-AOMK to the related Z-FK-AOMK and
modification of the lysine side chain with bulky organic fluorescent
dye resulted in a probe, GB123, that could be used to non-
invasively image cathepsins B and L activity [8,21]. Therefore, we
synthesized a probe in which the fluorescent reporter of GB123
was replaced by the 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-
tetraacetic acid (DOTA) for coordination of the
64Cu tracer (Z-
FK(DOTA)-AOMK; Figure 1B). We also synthesized a probe in
which the original carboxylbenzoyl (Z) capping group was
replaced by the DOTA group and an additional phenylalanine
amino acid was added to mimic the properties of the Z group that
was lost (GB170; Figure 1B). Finally, we generated a control
analog that lacked the reactive AOMK electrophile (GB173;
Figure 1B).
We radiolabeled the Z-FK(DOTA)-AOMK, GB-173 and GB-
170 conjugates with
64Cu (t1/2=12.7 h, Eb
+
max=656 keV, 19%)
at 50
0C for 1 h and purified the resulting probes to greater than
95% radiochemical purity using analytical RP-HPLC (Figure S1).
The specific radioactivity of
64Cu-Z-FK(DOTA)-AOMK was
0.48 Ci/mmol (17.8 MBq/nmol, 500 mCi/mg) at the end of
synthesis (EOS). The specific radioactivity of GB170 and GB173
were determined to be around 20 mCi/mg EOS. These labeled
compounds were then used for in vitro and in vivo labeling
experiments.
Labeling properties of
64Cu labeled AOMK analogs
We tested probes in the human breast cancer cell line MBA-
MB-435 and a mouse myoblastoma cell line that had been
transformed by over-expression of the ras oncogen (C2C12/Ras)
[26]. Both of these cell lines were originally used for in vivo imaging
studies with the NIRF-labeled cysteine cathepsin probes [21]. We
labeled both cell lines with GB123 and found that cathepsin B and
L activities of the C2C12/Ras cell line were higher than the
activities observed for the same targets in the MDA-MB-435 cells
(Figure 2A). Labeling of the same cells with
64Cu-Z-FK(DOTA)-
AOMK confirmed that the DOTA probes produced a similar
labeling pattern to that observed for GB123 (Figure 2B). In
addition, the specificity of the Cu-labeled probe for the cysteine
cathepsins was confirmed by the complete loss of labeling of the
protease targets when cells were pretreated with the general
cysteine cathepsin inhibitor JPM-OEt [25]. Finally, we compared
the labeling properties of the dual fluorescent and PET tagged
probe GB170 and GB173 to the original PET-only probe Z-
FK(DOTA)-AOMK. Both GB170 and GB173 have fluorescent
tags and can be used to directly label intact NIH 3T3 cells. For
comparison with the non-fluorescently labeled probe, we labeled
residual activity using a BODIPY-TMR labeled version of GB123
(Figure 2C). This analysis confirmed that the GB170 probe was
able to effectively label active cathepsins B and L. Interestingly, the
dual labeled probe GB170 showed slightly reduced potency in the
competition assay compared to Z-FK(DOTA)-AOMK and
GB123 even though it showed the most effective labeling of
cathepsins as measured by direct labeling. GB173, which lacks the
AOMK reactive group, failed to label active cathepsins and did
not compete for labeling by the BODIPY-TMR GB123, making it
an ideal negative control probe.
Biodistribution of
64Cu-labeled probe in subcutaneous
C2C12/Ras and MDA-MB-435 tumors
We next examined the overall biodistribution of the various
64Cu-labeled probes using athymic nude mice carrying subcuta-
neously grafted C2C12/Ras and MDA-MB-435 tumors. We
measured uptake of Z-FK(DOTA)-AOMK in both the C2C12/
Ras and MDA-MB-435 tumor models (Figure S2). This probe
displayed rapid blood clearance, resulting in low blood and muscle
uptake even at the early time points in both models. However, we
did observe some accumulation of radioactivity in the C2C12/Ras
tumors expressing high levels of cysteine cathepsins (0.356
0.13%ID/g at 0.5 h p.i.). This activity remained in the tumors
resulting in an uptake of 0.27 60.05%ID/g at 24 h p.i. For the
MDA-MB-435 tumors with lower cysteine cathepsin activity,
tumor uptake was significantly lower at each time point relative to
the C2C12/Ras tumors (P,0.05). Furthermore, while moderate
tumor-to-background ratios (tumor/blood 1.25 and tumor/muscle
5.64 at 2 h p.i.) were observed in the C2C12/Ras tumors, only
low tumor-to-background ratios (tumor/blood 0.61 and tumor/
muscle 3.03 at 2 h p.i.) were found for the MDA-MB-435 tumors.
For both tumor models,
64Cu-Z-FK(DOTA)-AOMK displayed
very low accumulation in most non-tumor tissues. The highest
radioactivity was found in the liver, consistent with high
endogenous expression of various cysteine cathepsins in this
organ. Moderate renal accumulation was also observed at all times
in both tumor models. These high levels of non-tumor signals may
be partially due to loss of the copper radiotracer from the probe.
This is an issue when using DOTA as a chelation agent.
Subsequent studies will be aimed at using more optimal chelators
and possibly other radio-tracers that can be secured to the probe
through covalent modification. Regardless, the relatively low
tumor accumulation of
64Cu-Z-FK(DOTA)-AOMK suggested
that this probe is not optimal for in vivo applications.
For comparison, we measured the biodistribution of GB170 as
well as its corresponding negative control GB173 in the C2C12/
Ras tumor model (Figure S2). GB170 rapidly accumulated in the
C2C12/Ras tumors (4.286 0.91%ID/g), with higher levels of
probe accumulation throughout all tissues compared to Z-
FK(DOTA)-AOMK. The control probe GB173 showed some
tumor accumulation (1.966 0.73%ID/g) but this level was
significantly (P,0.05) lower than the levels observed for GB170.
Furthermore, we observed moderate to high tumor-to-background
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GB170 in the C2C12/Ras tumors, while only low tumor-to-
background ratios (tumor/blood 1.84 and tumor/muscle 4.4 at
24 h p.i.) for GB173.
MicroPET imaging of cathepsin activity in tumor models
We performed micro PET imaging of mice bearing the MDA-
MB-435 and C2C12/Ras tumors using the
64Cu-Z-FK(DOTA)-
AOMK probe (Figure 3). Although the probe signal in the liver
and kidney is relatively high, the C2C12/Ras tumors could be
clearly visualized with good tumor to contralateral background
contrast of 2 at 24 h p.i. (Figure 3B). In contrast, we observed low
tumor uptake and poor tumor to normal tissue contrast in the
MDA-MB-435 tumors (Figure 3A). Quantification of the accu-
mulation of the probe in the tumor and contralateral muscle tissue
also showed that
64Cu-Z-FK(DOTA)-AOMK had higher tumor
uptake and a higher tumor-to-muscle ratio in C2C12/Ras than in
MDA-MB-435 (Figure 3B).
We next performed microPET imaging of mice bearing
C2C12/Ras tumors using
64Cu-GB170 and the corresponding
negative control,
64Cu-GB173 (Figure 4A). As expected, GB170
produced substantially higher signals that the
64Cu-Z-FK(DOTA)-
Figure 1. Mechanism and structures of activity-based imaging probes. (A) Mechanism of covalent inhibition of a cysteine protease by an
acyloxymethyl ketone. (B) Structures of the activity based probes GB123, Z-FK(DOTA)-AOMK, GB170 and GB173.
doi:10.1371/journal.pone.0028029.g001
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4 at 24 h p.i. In addition,
64Cu-GB173 showed only weak tumor
uptake and poor tumor to normal tissue contrast. Specific probe
uptake into tumors was confirmed by quantification of the tumor
and muscle signals (Figure 4B) and by comparison of tumor to
muscle and tumor to blood ratios (Figure 4C).
While these data were suggestive that probe accumulation
correlates with levels of active cathepsins in the tumor tissues, we
needed to demonstrate this correlation by direct analysis of
cathepsin actvity in samples after imaging. Therefore, we
performed a study in which three different cell lines were used
to generate xenograft tumors on nude mice. We chose the original
MDA-MB-435 cells with low cathepsin activity and used the
C2C12/Ras cells with high cathepsin levels. We also included a
third tumor cell line (4T1) that also has high expression of
cathepsins. We then performed PET imaging studies at various
time points using the GB170 probe (Figure 5A). After quantifica-
tion of tumor and muscle signals and subsequent biodistribution
studies of collected tissues (Figure S3), we lysed the tumor tissues
and analyzed both direct fluorescent labeling of cathepsins by the
GB170 probe (Figure 5B) and residual cathepsin activities in the
tumor lysates by addition of GB123 (Figure 5C). Subsequent
quantification of the intensity of labeling of residual cathepsins by
gel and comparison to levels of probe accumulation in tumors as
Figure 2. In vitro labeling properties of imaging probes. (A) Labeling of active cathepsins in the mouse myoblast cell line C2C12Ras, in the
humanbreast cancer cell line MDA-MB-435, or in NIH3T3 mousefibroblasts. Intactcellswerelabeled withGB123for1 hrfollowed bylysisandanalysis of
by SDS-PAGE and scanning of the gel for Cy5 fluorescence using a flatbed laser scanner (B) Labeling of cathepsins in C2C12/Ras and MDA-MB-435 cells.
Cells were pretreated with 50 mM JPM-OEt (+) or with control DMSO (-) for 2 h and labeled by addition of
64Cu-Z-FK(DOTA)-AOMK (555 KBq, 15 mCi) for
2 h. Cells were collected, lysed and analyzed by SDS-PAGE. The labeled proteases were visulized by phosphorimaging with a Typhoon 9410 scanner.
(C) NIH3T3 cells were incuabted with each probe at the indicated concentration for 1 hr followed by addition of a BODIPY-TMR-X-labeled GB111 probe.
Directly labeling of target cathepsins by probes was obtained by SDS-PAGE followe by scanning of the gel using a flatbed laser scanner (Top gel).
Inhibition of the same targets was observed by scanning of the gel for the BODIPY labeled probe using a Typhoon 9410 scanner (bottom gel).
doi:10.1371/journal.pone.0028029.g002
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PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e28029Figure 3. In vivo imaging of tumor-derived cathepsin activity using first generation activity-based probes. (A) Decay corrected coronal
(top) and transaxial (bottom) microPET images of a nude mouse bearing MDA-MB-435 tumor at 1, 4 and 28 hours after tail vein injection of
(5.55 MBq, 150 mCi)
64Cu-Z-FK(DOTA)-AOMK. The location of the tumor is indicated by arrows. Average values (n=3) for tumor uptake (%ID/g6SD)
relative to muscle signals at each time point are plotted (at right) (B) Decay corrected coronal (top) and transaxial (bottom) microPET images of a
nude mouse bearing C2C12/Ras tumors at 2, and 24 hr after administration of (3.7 MBq, 100 mCi)
64Cu-Z-FK(DOTA)-AOMK. Arrows indicated location
of tumors. Average values (n=3) for tumor uptake (%ID/g6SD) relative to muscle signals at each time point are plotted (at right). For all images (T:
tumor; L: liver; B: bladder).
doi:10.1371/journal.pone.0028029.g003
Figure 4. In vivo imaging of tumor-derived cathepsin activity using dual optical/PET imaging probes. (A) Coronal and transaxial decay
corrected microPET images of an athymic nude mouse bearing C2C12/Ras tumor at different time points after tail vein injection of (1.85 MBq, 50 mCi)
64Cu-GB170 (bottom) or
64Cu-GB173 (top). The location of the tumor is indicated by arrows. (B) Tumor-to-normal tissues ratios of
64Cu-GB170 or
64Cu-
GB173 in C2C12/Ras cancer bearing mice at different time points (n=3 each). (C) Plots of average ratios (n=3) of tumor to blood and tumor to
muscle signals at the indicated time points. For all images (T: tumor; L: liver; B: bladder).
doi:10.1371/journal.pone.0028029.g004
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the two set of values (Figure 5D). Specifically, the two high
expressors of cathepsins (4T1 and C2C12/Ras) showed indistin-
guishably (p=0.7) high levels of cathepsin activity as measured by
gel, while the tumors with low cathepsin activity (MDA-MB-435)
showed significantly (p,0.05) reduced levels of cathepsins relative
to either of the high cathepsin tumors. These levels matched the
relative levels of probe observed in tumors by PET imaging,
Figure 5. Probe signals in tumors correlate with levels of active cathepsins. (A) Representative coronal and transaxial decay corrected
microPET images of athymic nude mice bearing 4T1, MDA-MB-435 and C2C12/Ras tumors at different time points after tail vein injection of
(1.85 MBq, 50 mCi)
64Cu-GB170. Locations of tumors (T) and liver (L) are indicated. (B) SDS-PAGE and fluorescence scanning of tumor lysates from
mice in (A) after the final 24 hr time point. The positions of fluorescently labeled cathepsins are indicated. (C) Determination of residual cathepsin
activity in tumors from mice in (A) as measured by labeling of lysates with GB123 followed by SDS-PAGE and scanning of the gel with a flatbed laser
scanner. (D) Comparison of the levels of probe levels in tumor relative to muscle as measured by PET (right bar graph) to the levels of active
cathepsins as measured by quantification of gels in (C; left bar graph). The p-values are indicated and defined as follows: n.s.=not significant, *,0.05,
**,0.01, ***,0.001.
doi:10.1371/journal.pone.0028029.g005
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cysteine cathepsin activity.
Finally, to confirm that the probe accumulation was due to
modification of active cathepsins, we pre-treated C2C12/Ras
tumor bearing mice with a broad-spectrum inhibitor of the
cysteine cathepsins (Figure 6). This compound, K11777 was used
in previous optical imaging studies to pre-block cathepsin activity
[21]. MicroPET images show a marked drop in probe accumu-
lation in tumors of mice treated with the inhibitor compared to
those treated with the vehicle control (Figure 6A). Further
quantification of tumor signals in vehicle and drug-treated animals
compared to muscle signals confirmed the drop in specific signal as
a result of inhibition of cysteine cathepsin activity (Figure 6B).
Thus, virtually all of the probe signal observed above muscle
background could be blocked by inhibition of the target proteases.
Discussion
The cysteine cathepsins arepotentially valuable molecular targets
for tumor imaging because of their significant function in tumor
progression, invasion and metastasis [1-7]. Although NIRF labeled
probes that target this class of protease have been successfully
applied to optical imaging applications [10,13,15,16,21,22], radio-
active probes have not been developed. Part of the reason for the
lack of probes for radiological imaging applications is the difficulty
in designing radioactive probes based on protease substrates.
Therefore, in order to prepare new PET agents, we chose to make
use of highly selective activity-based probes that covalently target
proteases. The main disadvantage of using an inhibitor-based
approach is the lack of amplification of signal that is obtained
with substrate-based approaches. However, the high expression of
cysteine cathepsins in tumor tissue [27], and the prior validation of
these probes in optical imaging applications suggested that they
would be potentially valuable for use in PET imaging.
We chose to use the validated peptide AOMK scaffold for
development of our first generation PET probe. Simple conversion
of the Z-FK-AOMK probe to the corresponding DOTA labeled
analog Z-FK(DOTA)-AOMK (Figure 1B) allowed labeling with
64Cu. We selected
64Cu as a PET radiolabel because it can be
readily produced using a medical cyclotron and the intermediate
half-life of
64Cu makes it suitable for small molecule and peptide
radiolabeling [28-30]. Overall labeling and biodistribution studies
with
64Cu-Z-FK(DOTA)-AOMK indicated that the probe showed
rapid clearance in blood but accumulated in tumor tissues with
reasonable signal levels (Figure 3). Unfortunately, the probe
showed overall low tumor uptake (only 0.356 0.13%ID/g at 0.5 h
p.i. in C2C12/Ras tumor model), possibly due to its lipophilicity
(Figure S1) and loss of the fluorogenic Cy5 group found on the
corresponding optical imaging probe. We have found that the
addition of bulky aromatic groups on probes enhances their
labeling of lysosomal proteases, possibly due to increased
endocytosis. We therefore synthesized a PET probe in which the
Cy5 fluorophore was retained on the P1 lysine sidechain and the
DOTA tag for PET labeling was moved to the N-terminus of the
peptide. Analysis of the GB170 probe in microPET imaging
studies confirmed that the in vivo tumor uptake was clearly superior
to
64Cu-Z-FK(DOTA)-AOMK in C2C12/Ras tumor bearing
mice. We were also able to confirm that the signals observed for
the GB170 probe were due to retention at the site of active
cysteine cathepsins by showing correlation between imaging
signals and protease activity as measured biochemically (Figure 5)
as well as by showing a reduction in probe retention in mice
pretreated with a broad-spectrum inhibitor of the cathepsins
(Figure 6). These combined data confirm the selectivity of the
tumor signals and also demonstrates the utility of PET probes for
monitoring in vivo efficacy of small molecule drugs.
Although the probes reported here support the use of ABPs for
PET imaging, significant work will be required to improve the
probes. For example, release of free
64Cu from the radiolabeled
compound or transchelation to other proteins may also be partially
responsible for high background signal. Other chelators such as
cross-bridged cyclam ligands may also be used in place of DOTA to
improve the metal-chelate stability and subsequently improve the
biodistribution of the probes [30,31]. Regardless of the issues of
probe background, the use of positron emitting labels allows
application of tomographic methods to resolve signals in specific
locations that are free from high protease background. In addition,
unlike the NIRF versions of these ABPs the PET probes have the
potential to be used to image tissues at much greater depths and
with higher overall resolution [21]. The work presented here with
64Cu-labeled probes serves as the foundation for future studies using
the more clinically suitable
18F tracer. We believe that cathepsin-
targeted PET imaging agents should find broad applications once
these agents become available to the nuclear medicine community.
Figure 6. Inhibition of tumor-derived cathepsin activity can be
visualized non-invasively using PET probes. Coronal and
transaxial decay corrected microPET images of an athymic nude mouse
bearing MDA-MB-231MFP tumors treated with the general cathepsin
inhibitor K11777 (treated) or vehicle (control) followed by
64Cu-GB170
(1.85 MBq, 50 mCi). Images were taken at the indicated times after
injection of the imaging probe. The location of the tumor is indicated
by arrows. (B) Quantification of average levels (n=3) of probe uptake in
tumors at the various time points for control treated and inhibitor
treated mice relative to uptake into muscle tissue. For all images (T:
tumor; L: liver; B: bladder).
doi:10.1371/journal.pone.0028029.g006
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Ethics Statement
All animal experiments were conducted according to relevant
national and international guidelines and approved by the
Stanford Institutional Animal Care and Use Committee (IACUC;
approval number A3213-01). All experiments strictly followed the
panel’s specific guidelines regarding the care, treatment and
euthanasia of animals used in the study.
General
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)
was obtained from Macrocyclics Inc. (Richardson, TX). All other
chemicals were obtained from Sigma-Aldrich Chemical Co. (St.
Louis, MO). AOMK analogs, were prepared based on a reported
synthetic method [20].
64Cu was provided by the Department of
Medical Physics,University of Wisconsin at Madison (Madison,WI).
A CRC-15R PET dose calibrator (Capintec Inc., Ramsey, NJ) was
used for all radioactivity measurements. Reverse phase high
performance liquid chromatography (RP-HPLC) was performed
on a Dionex Summit HPLC system (Dionex Corporation,
Sunnyvale, CA) equipped with a 170U 4-Channel UV-Vis
absorbance detector and radioactivity detector (Carroll & Ramsey
Associates, model 105S, Berkeley, CA). UV detection wavelengths
were 218 nm, 254 nm and 280 nm for all the experiments.
Both semi-preparative (Vydac, Hesperia, CA. 218TP510-C18,
10 mm6250 mm) and analytical (Dionex, Sunnyvale, CA. Ac-
claim120 C18, 4.6 mm250 mm) RP-HPLC columns were used.
The mobile phase was solvent A, 0.1% trifluoroacetic acid (TFA)/
H2O, and solvent B, 0.1%TFA/acetonitrile. Matrix-assisted laser
desorption/ionization time of flight mass spectrometry (MALDI-
TOF-MS) were performed on a Perseptive Voyager-DE RP
Biospectrometry instrument (Framingham, MA) by the Stanford
Protein and Nucleic Acid Biotechnology Facility. Alpha cyano-4-
hydroxy-cinnamic acid (a-CHCA, prepared as 10 g/L in 33.3%
CH3CN : 33.3% EtOH : 33.3% H2O : 0.1% TFA) were used as the
solid matrix.NIH3T3mouse fibroblast cellswasa generousgiftfrom
Dr. P. Jackson, Stanford University, CA. The tumorigenic murine
skeletal myoblast cell line C2C12/Ras (retrovirally transduced with
the ras oncogene) was a generous gift from Dr. Helen Blau, Stanford
University, CA, human breast cancer MDA-MB-435 were a
generous gift from Dr. X. Chen, Stanford University, CA. 4T1 cells
were purchased ATCC. All the cells were original tested for
microbial contamination, growth properties, morphology and
species (COI assay) by the labs or vendor from where they were
obtained and kept in culture for less than 6 months from
resuscitation from frozen stocks. Female athymic nude mice (nu/
nu) were purchased from Charles River Laboratories (Boston, MA).
Chemistry and Radiochemistry
For details on the synthesis and radiolabeling of compounds
please see Methods S1.
Labeling Intact Tumor Cells with
64Cu Labeled ABP
C2C12/Ras and MDA-MB-435 cells (0.25 M each well) were
seeded in a six-well plate one day before the study. Cells were
pretreated with the general papain family protease inhibitor JPM-
OEt (50 mM) [25] or with control DMSO (0.1%) for 1 h and
labeled by addition of
64Cu-Z-FK(DOTA)-AOMK (555 KBq,
15 mCi) to culture medium for 2 h. Cells was then washed with
PBS and lysed. Equal amounts of protein per lane were separated
by 12% SDS-PAGE. The gel was dried and exposed to a
phosphorimager screen. The labeled proteases were visualized by
scanning of the phosphorimager screen with a Typhoon 9410
imager (GE Healthcare, Piscataway, NJ). The labeled bands were
quantified with ImageJ 1.36b (public domain software from
National Institute of Health).
Labeling Intact Tumor Cells with AOMK analogs
NIH3T3andC2C12Rascellswerecultured inDMEM(GIBCO)
supplemented with 10% fetal bovine serum (FBS; GIBCO), 100
units per mL penicillin and 100 mg per mL streptomycin (GIBCO).
MDA-MB-435 cells were cultured in Leibovitz’s L-15 medium
(GIBCO) supplemented with 10%FBS, 100 units per mL penicillin
and 100 mg per mL streptomycin (GIBCO). NIH3T3 cells (0.25 M
each well) were seeded in a six-well plate one day before the study.
Cells were pretreated with the general papain family protease
inhibitor JPM-OEt (50 mM;[25] or with control DMSO (0.1%) for
1 h and labeled by addition of AOMK analogs to culture medium
for2 h.CellswasthenwashedwithPBSandlysed.Equalamountsof
protein per lane were separated by 12% SDS-PAGE. The gel was
dried and exposed to a phosphorimager screen. The labeled
proteases were visualized by scanning of the phosphorimager screen
with a Typhoon 9410 imager (excitation/emission 633/680 nm)
(GE Healthcare, Piscataway, NJ). For the Competition experiment,
NIN3T3 cells were treated similarly as described above but were
labeled with GB111-TMR-X (1 mM final concentration) after probe
treatment and then lysed. Gells were scanned for fluorescence at
532/580 nm with a Typhoon scanner.
Subcutaneous Tumor Model
All animalstudies werecarried outincompliance with Federal and
local institutional rules for the conduct of animal experimentation.
Female athymic nude mice (nu/nu) were obtained from Charles River
Laboratories (Boston, MA) at 7–8 weeks old and kept under sterile
conditions. The nude mice were inoculated subcutaneously in the
right shoulder with 1610
6 cultured C2C12/Ras cells or 5610
6
MDA-MB-435 cells or 3610
6 cultured 4T1 cells. For inhibition
studies, 3610
6 MDA-MB-231 MFP cells were used. When the
tumors reached 0.5–0.8 cm in diameter, the tumor bearing micewere
were used for in vivo PET imaging studies (see below).
MicroPET Imaging
PET imaging of tumor-bearing mice will be performed on a
microPET R4 rodent model scanner (Siemens Medical Solutions
USA, Inc., Knoxville, TN). The mice bearing C2C12/Ras and
MDA-MB-435 tumors were injected with 740 KBq (20 mCi)
64Cu
AOMK probe via the tail vein. At different times after injection, 5 or
10-minstaticscanswereobtainedand theimageswerereconstructed
by a two-dimensional ordered subsets expectation maximum
(OSEM) algorithm. Regions of interest (ROIs) were then drawn
over the tumor on decay-corrected whole-body coronal images. The
mean counts per pixel per minute were obtained from the ROI and
converted to counts per milliliter per minute by using a calibration
constant. By assuming a tissue density of 1 g/mL, the ROIs were
converted to counts/g/min. An image ROI-derived %ID/g of tissue
was then determined by dividing counts per gram per minute with
injected dose (ID). No attenuation correction was performed.
Biodistribution Studies
Mice bearing xenografts were injected with 740 KBq (20 mCi)
of
64Cu labeled tracer through the tail vein and sacrificed at
different time points after injection. Tumor and normal tissues
were removed and weighed, and radioactivity was measured by
gamma-counter. The radioactivity uptake in the tumor and
normal tissues was expressed as a percentage of the injected
radioactive dose per gram of tissue (%ID/g). To inhibit the in vivo
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dose of 100 mg/kg/day in 40% DMSO/sterile PBS in a final
volume of 100 mL for 5 days before the imaging sessions [21].
Biochemical analysis of cathepsin activity in tumors
Tumors were removed after the 24 hr time point and
homogenized in citrate buffer (50mM Citrate pH 5.5, 5 mM
DDT, 0.5% CHAPS, 0.1% Triton X). Total protein (40 mg) was
labeled withGB123 (1 mM final concentration) for 1 hrat 37uC, the
proteins were resolved on SDS-PAGE (15%). Labeled proteases
were visualized by scanning the gel with a Typhoon 9410 imager
(excitation/emission 633/680 nm) (GE Healthcare, Piscataway,
NJ). Labeling intensities were quantified using Image J software.
Statistical Method
Statistical analysis was performed using the Student’s t-test for
unpaired data. A 95% confidence level was chosen to determine the
significance between groups, with P,0.05 being significantly different.
Supporting Information
Figure S1 Characterization and purification PET
probes. HPLC radiochromatogram of purified (A)
64Cu-Z-
FK(DOTA)-AOMK (B)
64Cu-GB170, and (C)
64Cu-GB173.
(DOC)
Figure S2 Biodistribution of probes in vivo. Biodistribu-
tion results of
64Cu-Z-FK(DOTA)-AOMK in (A) C2C12/Ras
(top) or MDA-MB-435 (bottom) cancer bearing mouse models as
well for (B)
64Cu-GB170 (top) and
64Cu-GB173 (bottom) in
C2C12/ras tumor bearing mice. Data are expressed as the
percentage administered activity (injected dose) per gram of tissue
(%ID/g) after intravenous injection of 740 kBq (20 mCi) of
64Cu-
Z-FK(DOTA)-AOMK at 0.5, 2, and 24 h pi (n=3). Significant
lower tumor uptake and tumor/blood, tumor/muscle ratio in
MDA-MB-435 breast cancer (P,0.05) were observed.
(DOC)
Figure S3 Biodistribution of
64Cu-GB170 in tumor
bearing mice. N=4 for each.
(DOC)
Methods S1 Chemistry and Radiochemistry.
(DOC)
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